warning icon

COVID-19 DEW Report, powered by Reformulary®Read more


Merck sees a positive in early mulnupiravir trial

Merck has announced early results from trials done on mulnupiravir, an influenza drug, that show it reduces the time it takes for COVID-19 positive individuals to test negative after having symptoms associated with the disease. From a 200 participant trial, the group receiving mulnupiravir had no members showing viral loads after 5 days, while the group receiving placebo saw 24% of members with viral loads.

Published: March 8, 2021

Fierce BioTech

Read Article